296 related articles for article (PubMed ID: 18408969)
1. Lymphangioleiomyomatosis and tuberous sclerosis complex.
Chorianopoulos D; Stratakos G
Lung; 2008; 186(4):197-207. PubMed ID: 18408969
[TBL] [Abstract][Full Text] [Related]
2. Pathogenesis of multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis genes TSC1 and TSC2.
Maruyama H; Ohbayashi C; Hino O; Tsutsumi M; Konishi Y
Pathol Int; 2001 Aug; 51(8):585-94. PubMed ID: 11564212
[TBL] [Abstract][Full Text] [Related]
3. Clinical and molecular insights into lymphangioleiomyomatosis.
Steagall WK; Taveira-DaSilva AM; Moss J
Sarcoidosis Vasc Diffuse Lung Dis; 2005 Dec; 22 Suppl 1():S49-66. PubMed ID: 16457017
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
5. Metastasis of benign tumor cells in tuberous sclerosis complex.
Henske EP
Genes Chromosomes Cancer; 2003 Dec; 38(4):376-81. PubMed ID: 14566858
[TBL] [Abstract][Full Text] [Related]
6. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.
Smolarek TA; Wessner LL; McCormack FX; Mylet JC; Menon AG; Henske EP
Am J Hum Genet; 1998 Apr; 62(4):810-5. PubMed ID: 9529362
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.
Carsillo T; Astrinidis A; Henske EP
Proc Natl Acad Sci U S A; 2000 May; 97(11):6085-90. PubMed ID: 10823953
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis.
Sato T; Seyama K; Fujii H; Maruyama H; Setoguchi Y; Iwakami S; Fukuchi Y; Hino O
J Hum Genet; 2002; 47(1):20-8. PubMed ID: 11829138
[TBL] [Abstract][Full Text] [Related]
9. TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.
Lesma E; Ancona S; Sirchia SM; Orpianesi E; Grande V; Colapietro P; Chiaramonte E; Di Giulio AM; Gorio A
J Cell Mol Med; 2014 May; 18(5):766-79. PubMed ID: 24606538
[TBL] [Abstract][Full Text] [Related]
10. Lymphangioleiomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex.
Tian X; Glass JE; Kwiatkowski DJ; Towbin AJ; Li Y; Sund KL; Krueger DA; Franz DN; McCormack FX; Gupta N
Ann Am Thorac Soc; 2021 May; 18(5):815-819. PubMed ID: 33171065
[No Abstract] [Full Text] [Related]
11. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis.
Astrinidis A; Khare L; Carsillo T; Smolarek T; Au KS; Northrup H; Henske EP
J Med Genet; 2000 Jan; 37(1):55-7. PubMed ID: 10633137
[TBL] [Abstract][Full Text] [Related]
12. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
13. Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM.
Lesma E; Grande V; Ancona S; Carelli S; Di Giulio AM; Gorio A
PLoS One; 2008; 3(10):e3558. PubMed ID: 18958173
[TBL] [Abstract][Full Text] [Related]
14. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis.
Strizheva GD; Carsillo T; Kruger WD; Sullivan EJ; Ryu JH; Henske EP
Am J Respir Crit Care Med; 2001 Jan; 163(1):253-8. PubMed ID: 11208653
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions.
Liu HJ; Krymskaya VP; Henske EP
Chest; 2019 Dec; 156(6):1062-1067. PubMed ID: 31437431
[TBL] [Abstract][Full Text] [Related]
16. Multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis with a TSC2 gene.
Maruyama H; Seyama K; Sobajima J; Kitamura K; Sobajima T; Fukuda T; Hamada K; Tsutsumi M; Hino O; Konishi Y
Mod Pathol; 2001 Jun; 14(6):609-14. PubMed ID: 11406664
[TBL] [Abstract][Full Text] [Related]
17. Lymphangioleiomyomatosis.
Xu KF; Xu W; Liu S; Yu J; Tian X; Yang Y; Wang ST; Zhang W; Feng R; Zhang T
Semin Respir Crit Care Med; 2020 Apr; 41(2):256-268. PubMed ID: 32279296
[TBL] [Abstract][Full Text] [Related]
18. Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC).
Kwiatkowski DJ
Lymphat Res Biol; 2010 Mar; 8(1):51-7. PubMed ID: 20235887
[TBL] [Abstract][Full Text] [Related]
19. EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.
Taveira-DaSilva AM; Moss J
Expert Opin Orphan Drugs; 2016; 4(4):369-378. PubMed ID: 27833825
[TBL] [Abstract][Full Text] [Related]
20. [Clinical and molecular epidemiology of lymphangioleiomyomatosis and pulmonary pathology in tuberous sclerosis].
Urban T
Rev Mal Respir; 2000 Jun; 17(2 Pt 2):597-603. PubMed ID: 10939121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
